

Applicant : Carl-Axel E. [redacted] et al.
Serial No. :
Filed : Herewith
Page : 3

[redacted]ey's Docket No.: 06275-150003

REMARKS

Claims 1 to 10 are pending in this application. Claims 5, 6, 7, 8, and 10 have been amended to delete multiple dependency. No new matter has been added.

Attached is a marked-up version of the changes being made by the current amendment.

Please apply any other charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date:

Nov. 13, 2001

[Signature]
Janis K. Fraser, Ph.D., J.D.
Reg. No. 34,819

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20343606.doc

10010282 "E820T001

Version with markings to show changes made

In the claims:

Claims 5, 6, 7, 8, and 10 have been amended as follows:

5. Use according to [any one of the preceding claims] claim 1 wherein the first active ingredient is formoterol fumarate dihydrate.

6. Use according to [any one of the preceding claims] claim 1 wherein the molar ratio of the first active ingredient to the second active ingredient is from 1:555 to 2:1 preferably from 1:70 to 1:4.

7. Use of formoterol a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt in the manufacture of a composition as defined in claim 1 [or 2 or a kit as defined in claim 3 or 4] for use in the treatment of chronic obstructive pulmonary disease.

8. Use of budesonide in the manufacture of a composition as defined in claim 1 [or 2 or a kit as defined in claim 3 or 4] for use in the treatment of chronic obstructive pulmonary disease.

10. A method for the treatment of a patient suffering from chronic obstructive pulmonary disease which method comprises administering to the patient via inhalation a therapeutically effective amount of a composition as defined in claim 1 [or 2].

10010223 111301
T0E1T 0820T001